Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

BACKGROUND: Immune‐related adverse events (irAEs) should be anticipated with treatment by immune checkpoint inhibitors (ICIs). Although the relationship between irAEs and efficacy of ICI has been reported, it has not yet been clarified whether the benefit from ICI outweighs the low frequency of proc...

Full description

Saved in:
Bibliographic Details
Published in:Thorac Cancer
Main Authors: Komiya, Kazutoshi, Nakamura, Tomomi, Abe, Tomonori, Ogusu, Shinsuke, Nakashima, Chiho, Takahashi, Koichiro, Kimura, Shinya, Sueoka‐Aragane, Naoko
Format: Artigo
Language:Inglês
Published: John Wiley & Sons Australia, Ltd 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718019/
https://ncbi.nlm.nih.gov/pubmed/31328416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13149
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items